What Is So Bad About a Hemoglobin Level of 12 to 13 g/dL for Chronic Kidney Disease Patients Anyway?

Advances in Chronic Kidney Disease

Volumn 16, Issue 2, 2009, Pages 131-142

  Besarab, Anatole ^a   Frinak, Stanley ^a   Yee, Jerry ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anemia; Chronic kidney disease; Erythropoiesis stimulating agent; Iron deficiency

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DEATH; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INFLAMMATION; IRON DEFICIENCY; LOW DRUG DOSE; MALNUTRITION; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; THROMBOSIS;

ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; PROGNOSIS;

EID: 60149101104     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.12.007     Document Type: Article

References (70)

1. Medicare Intermediary Manual Part 3: Claims Process. Transmittal No 1545, Health Care Financing Administration, October 1989
2. Eschbach J.W., Egrie J.C., Downing M.R., et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316 (1987) 73-78
3. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 (1989) 992-1000
4. Eschbach J.W., and Adamson J.W. Guidelines for recombinant human erythropoietin therapy. Am J Kidney Dis 4 (1989) 2-8
5. Duff D.R., Golper T.A., Sloan R.S., et al. Low-dose recombinant human erythropoietin therapy in chronic hemodialysis patients. Am J Kidney Dis 18 (1991) 60-64
6. Besarab A. Optimizing epoetin therapy in end-stage renal disease: The case for subcutaneous administration. Am J Kidney Dis 22 (1993) 13-22
7. Collins A.J., Kasiske B., Herzog C., et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 49 (2007) S1-S296
8. NKF-DOQI: Clinical practice guidelines for vascular access. Am J Kidney Dis 30 (1997) S150-S189
9. NKF-K/DOQI Clinical Practice Guidelines for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 (2006) S11-S145
10. NKF-KDOQI Oqi Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2001. Am J Kidney Dis 37 (2001) S182-238
11. Canadian Society of Nephrology Guidelines. Available at: http://csnscn.ca/local/files/guidelines/CSN-Guidelines-1999.pdf. Accessed November 14, 2008
12. Locatelli F., Alajama P., Barany P., et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 19 (2004) 1-47
13. CARI. Available at: www.cari.org.au/dialysis_bht_updating.php, 2005. Accessed November 01, 2008
14. Casadevall N., Nataf J.B., Viron B., et al. Pure red-cell aplasia and a\antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Eng J Med 346 (2005) 469-475
15. Collins A.J., Li S., Adamson J.W., et al. Assessment of pure red cell aplasia in US dialysis patients: The limits of the Medicare data. Am J Kidney Dis 43 (2004) 464-470
16. Besarab A., Flaherty K.K., Erslev A., et al. Clinical pharmacology and economics of recombinant human erythropoietin: The case for subcutaneous administration. J Am Soc Nephrol 2 (1992) 1405-1416
17. Besarab A., Reyes C.M., and Hornberger J.C. Meta-analysis of subcutaneous versus intravenous epoetin administration in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (2002) 439-446
18. Collins A.J., Kasiske B., Herzog C., et al. Excerpts from the United States Renal Data System 2006 Annual Data Report. Am J Kidney Dis 49 (2007) A6-A7 S1-S296
19. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Engl J Med 339 (1998) 584-590
20. Parfrey P.S., Foley R.N., Wittreich B.H., et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 (2005) 2180-2189
21. Foley R.N., Parfrey P.S., Morgan J., et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58 (2000) 325-1335
22. Furuland H., Linde T., Ahlmen J., et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 18 (2003) 353-361
23. Drueke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
24. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
25. Ritz E., Laville M., Bilous R.W., et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 49 (2007) 194-207
26. Gouva C., Nikolopoulos P., Ioannidis J.P., et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66 (2004) 753-760
27. Rossert J., Levin A., Roger S.D., et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 47 (2006) 738-750
28. Macdougall I.C., Temple R.M., and Kwan J.T. Is early treatment of anaemia with epoetin-{alpha} beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 22 (2007) 784-793
29. Roth D., Smith R.D., Schulman G., et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24 (1994) 777-784
30. Kuriyama S., Tomonari H., Yoshida H., et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77 (1997) 176-185
31. Strippoli G.F., Craig J.C., Manno C., et al. Hemoglobin targets for the anemia of chronic kidney disease: A meta-analysis of randomized, controlled trials. J Am Soc Nephrol 15 (2004) 3154-3165
32. Phrommintikul A., Haas S.J., Elsik M., et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369 (2007) 381-388
33. Roger S.D., and Levin A. Epoetin trials: Randomised controlled trials don't always mimic observational data. Nephrol Dial Transplant 22 (2007) 684-686
34. Strippoli G.F., Tognoni G., Navaneethan S.D., et al. Haemoglobin targets: We were wrong, time to move on. Lancet 369 (2007) 346-350
35. U.S. Food & Drug Administration: FDA Strengthens Safety Information for Erythropoiesis-Stimulating Agents (ESAs). Available at: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01582.html. Accessed September 2, 2008
36. U.S. Food & Drug Administration: Erythropoiesis Stimulating Agents. Available at: http://www.fda.gov/medwatch/safety/2007/safety07.htm#ESA. Accessed October 9, 2008
37. Besarab A., Frankenfield D., Johnson C., et al. The severely anemic adult hemodialysis patient: observations from CMS's ESRD Clinical Performance Measures (CPM) Project. J Am Soc Nephrol 18 (2007) 282A
38. US Renal Data System. US Renal Data System annual data report, atlas of endstage renal disease in the United States (2007). Available at: http://www.usrds.org/adr.htm. Accessed August 4, 2008
39. Collins A.J., Li S., St Peter W., et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2 (2001) 2465-2473
40. Thamer M., Zhang Y., Kaufman J., et al. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA 297 (2007) 1667-1674
41. Regidor D.L., Kopple J.D., Kovesdy C.P., et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17 (2006) 1181-1191
42. Szczech L.A., Barnhart H.X., Jula K., et al. Secondary analysis of the CHOIR trial epoetin-A dose and achieved hemoglobin outcomes. Kidney Int 74 (2008) 791-798
43. Cotter D., Zhang Y., Thamer M., et al. The effect of epoetin dose on hematocrit. Kidney Int 73 (2008) 347-353
44. Kilpatrick R.D., Critchlow C.W., Fishbane S., et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 3 (2008) 1077-1083
45. U.S. Food and Drug Administration: FDA Advisory Committee Briefing Document; Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee; and errata. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf and http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-02-FDA-Errata%20.pdf. Accessed September 4, 2008
46. Eschbach J.W., Abdulhadi M.H., Browne J.K., et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III multicenter clinical trial. Ann Intern Med 111 (1989) 992-1000
47. Zhang Y., Thamer M., Stefanik K., et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 44 (2004) 866-876
48. Fishbane S., and Besarab A. On the mechanisms of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2 (2007) 1274-1282
49. Tang W.W., Stead R.A., and Goodkin D.A. Effects of epoetin alfa on hemostasis in chronic renal failure. Am J Nephrol 18 (1998) 263-273
50. Piccin A., Murphy W.G., and Smith O.P. Circulating microparticles: Pathophysiology and clinical implications. Blood Rev 21 (2007) 157-171
51. Mallat Z., Hugel B., Ohan J., et al. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque thrombogenicity. Circulation 99 (1999) 348-353
52. Movilli E., Pertica N., Camerini C., et al. Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy. Am J Kidney Dis 39 (2002) 850-853
53. Saran R., Bragg-Gresham J.L., Rayner H.C., et al. Nonadherence in hemodialysis: Associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 64 (2003) 254-262
54. Pedersen J.H., Esbensen K., Standeven K.F., et al. Fibrin clot structure in patients with end-stage renal disease Thromb Haemost 98 (2007) 339-345
55. Dahl N.V., Henry D.H., and Coyne D.W. Thrombosis with erythropoietic stimulating agents-does iron-deficient erythropoiesis play a role?. Semin Dial 21 (2008) 210-211
56. Streja E., Kovesdy C.P., Greenland S., et al. Erythropoietin, iron depletion, and relative Thrombocytosis: A possible explanation for the hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 52 (2008) 727-736
57. Beguin Y. Erythropoietin and platelet production. Haematologica 84 (1999) 541-547
58. Beguin Y., Loo M., R'Zik S., et al. Effect of recombinant human erythropoietin on platelets in patients with anemia of renal failure: Correlation of platelet count with erythropoietic activity and iron parameters. Eur J Haematol 53 (1994) 265-270
59. Cid J., and Lozano M. Hemoglobin levels and platelet counts after iron therapy in iron deficiency anemia. Haematologica 83 (1998) 749
60. Coyne D.W., Kapoian T., Suki W., et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 18 (2007) 975-984
61. Henry DH, Dahl NV, Auerbach M: Is thromboembolism in cancer patients treated with erythropoietic stimulating agents related to thrombocytosis and iron restricted erythropoiesis? [abstract] Blood 110:485A, 2007. Accessed Jan 16, 2009 at: http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/1625
62. Guntupalli K., Soffer O., and Baciewicz P. Pulmonary embolism in end stage renal disease. Intensive Care Med 16 (1990) 405-407
63. Casserly L.F., Reddy S.M., and Dember L.M. Venous thromboembolism in end-stage renal disease. Am J Kidney Dis 36 (2000) 405-411
64. Tveit D.P., Hypolite I.O., Hsieh P., et al. Chronic dialysis patients have a high risk for pulmonary embolism. Am J Kidney Dis 39 (2002) 1011-1017
65. Diaz-Ricart M., Etebanell E., Cases A., et al. Erythropoietin improves signaling through tyrosine phosphorylation in platelets from uremic patients. Thromb Haemost 82 (1999) 1312-1317
66. Homoncik M., Jilma-Stohlawetz P., Schmid M., et al. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: A randomized, double blind, placebo-controlled study. Aliment Pharmacol Ther 20 (2004) 437-443
67. Carlini R.G., Dusso A.S., Obialo C.I., et al. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 43 (1993) 1010-1014
68. Wada Y., Matsuoka H., Tamai O., et al. Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am J Hypertens 12 (1999) 980-987
69. Morikawa K., Kuroda M., and Hasegawa T. Is the intracellular calcium mediated pathway involved in erythropoietin-induced hypertension?. Nephron 65 (1993) 503-504
70. Azzadin A., Bialkowska A., Buczko W., et al. Serotonergic mechanism of erythropoietin-induced hypertension. Nephrol Dial Transplant 7 (1992) 882-883